207 related articles for article (PubMed ID: 37841281)
41. Exploration of Potential Integrated Models of N6-Methyladenosine Immunity in Systemic Lupus Erythematosus by Bioinformatic Analyses.
Zhao X; Ge L; Wang J; Song Z; Ni B; He X; Ruan Z; You Y
Front Immunol; 2021; 12():752736. PubMed ID: 35197962
[TBL] [Abstract][Full Text] [Related]
42. Bioinformatics analysis of differentially expressed gene profiles associated with systemic lupus erythematosus.
Wu C; Zhao Y; Lin Y; Yang X; Yan M; Min Y; Pan Z; Xia S; Shao Q
Mol Med Rep; 2018 Mar; 17(3):3591-3598. PubMed ID: 29257335
[TBL] [Abstract][Full Text] [Related]
43. Potential therapeutic target genes for systemic lupus erythematosus: a bioinformatics analysis.
Yu Y; Liu L; Hu LL; Yu LL; Li JP; Rao JA; Zhu LJ; Liang Q; Zhang RW; Bao HH; Cheng XS
Bioengineered; 2021 Dec; 12(1):2810-2819. PubMed ID: 34180358
[TBL] [Abstract][Full Text] [Related]
44. Immunogenetics of systemic lupus erythematosus: A comprehensive review.
Ghodke-Puranik Y; Niewold TB
J Autoimmun; 2015 Nov; 64():125-36. PubMed ID: 26324017
[TBL] [Abstract][Full Text] [Related]
45. Identification of biomarkers related to neutrophils and two molecular subtypes of systemic lupus erythematosus.
Li H; Yang P
BMC Med Genomics; 2022 Jul; 15(1):162. PubMed ID: 35858908
[TBL] [Abstract][Full Text] [Related]
46. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies.
Hua J; Kirou K; Lee C; Crow MK
Arthritis Rheum; 2006 Jun; 54(6):1906-16. PubMed ID: 16736505
[TBL] [Abstract][Full Text] [Related]
47. Revealing the Immune Heterogeneity between Systemic Lupus Erythematosus and Rheumatoid Arthritis Based on Multi-Omics Data Analysis.
Zhang Y; Lee TY
Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563556
[TBL] [Abstract][Full Text] [Related]
48. TMT-based quantitative proteomics analysis and potential serum protein biomarkers for systemic lupus erythematosus.
Zhou G; Wei P; Lan J; He Q; Guo F; Guo Y; Gu W; Xu T; Liu S
Clin Chim Acta; 2022 Sep; 534():43-49. PubMed ID: 35810799
[TBL] [Abstract][Full Text] [Related]
49. Screening of Potential Circulating Diagnostic Biomarkers and Molecular Mechanisms of Systemic Lupus Erythematosus-Related Myocardial Infarction by Integrative Analysis.
Ding H; Zhu G; Lin H; Chu J; Yuan D; Yao Y; Gao Y; Chen F; Liu X
J Inflamm Res; 2023; 16():3119-3134. PubMed ID: 37520666
[TBL] [Abstract][Full Text] [Related]
50. Type I interferon gene signature test-low and -high patients with systemic lupus erythematosus have distinct gene expression signatures.
Brohawn PZ; Streicher K; Higgs BW; Morehouse C; Liu H; Illei G; Ranade K
Lupus; 2019 Nov; 28(13):1524-1533. PubMed ID: 31660791
[TBL] [Abstract][Full Text] [Related]
51. RNA-seq of circular RNAs identified circPTPN22 as a potential new activity indicator in systemic lupus erythematosus.
Miao Q; Zhong Z; Jiang Z; Lin Y; Ni B; Yang W; Tang J
Lupus; 2019 Apr; 28(4):520-528. PubMed ID: 30871426
[TBL] [Abstract][Full Text] [Related]
52. Coordination of retrotransposons and type I interferon with distinct interferon pathways in dermatomyositis, systemic lupus erythematosus and autoimmune blistering disease.
Kuriyama Y; Shimizu A; Kanai S; Oikawa D; Motegi SI; Tokunaga F; Ishikawa O
Sci Rep; 2021 Nov; 11(1):23146. PubMed ID: 34848794
[TBL] [Abstract][Full Text] [Related]
53. Bioinformatics analysis of the pathogenic link between Epstein-Barr virus infection, systemic lupus erythematosus and diffuse large B cell lymphoma.
Zhu QY
Sci Rep; 2023 Apr; 13(1):6310. PubMed ID: 37072474
[TBL] [Abstract][Full Text] [Related]
54. A ceRNA regulatory network in systemic lupus erythematosus and its molecular interplay with cancer.
Lin S; Fan R; Li W; Hou W; Lin Y
Ann Transl Med; 2022 May; 10(10):563. PubMed ID: 35722400
[TBL] [Abstract][Full Text] [Related]
55. Bone marrow as a target organ of systemic lupus erythematosus: analysis of cases with myelofibrosis.
Üsküdar Cansu D; Üsküdar Teke H; Işiksoy S; Korkmaz C
Int J Rheum Dis; 2018 May; 21(5):1049-1059. PubMed ID: 29671953
[TBL] [Abstract][Full Text] [Related]
56. IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.
Rodríguez-Carrio J; López P; Alperi-López M; Caminal-Montero L; Ballina-García FJ; Suárez A
Front Immunol; 2018; 9():3085. PubMed ID: 30666255
[No Abstract] [Full Text] [Related]
57. Signaling Pathways of Type I and Type III Interferons and Targeted Therapies in Systemic Lupus Erythematosus.
Chyuan IT; Tzeng HT; Chen JY
Cells; 2019 Aug; 8(9):. PubMed ID: 31450787
[TBL] [Abstract][Full Text] [Related]
58. Identification of m6A-Related Biomarkers in Systemic Lupus Erythematosus: A Bioinformation-Based Analysis.
Tian Y; Tao K; Li S; Chen X; Wang R; Zhang M; Zhai Z
J Inflamm Res; 2024; 17():507-526. PubMed ID: 38298525
[TBL] [Abstract][Full Text] [Related]
59. The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus.
Fu Q; He Q; Dong Q; Xie J; Geng Y; Han H; Huang Y; Lu J; Zeng Z; Wang W; Chen K; Zhan X
Clin Chim Acta; 2022 Jan; 524():69-77. PubMed ID: 34742679
[TBL] [Abstract][Full Text] [Related]
60. Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry.
Rector I; Owen KA; Bachali P; Hubbard E; Yazdany J; Dall'era M; Grammer AC; Lipsky PE
RMD Open; 2023 Sep; 9(3):. PubMed ID: 37709528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
